DOWNLOAD (PDF): VCS FACT SHEET – Obstructive Sleep Apnea (OSA) Health Risks Without and With CPAP/PAP Treatment
Veterans for Common Sense
FACT SHEET: Obstructive Sleep Apnea (OSA) Health Risks Without and With CPAP/PAP Treatment
Updated August 13, 2026
| OSA Health Consequence: | Untreated OSA Associated With: | OSA When Treated with PAP: | Has PAP been shown to eliminate the excess risk in OSA? | ||
| Sleep symptoms* | OSA produces snoring, disrupted sleep, fatigue and impaired daytime functioning. [1][10] | YES. PAP clearly improves sleep symptoms in many patients. [1][10] | YES, while PAP is used. PAP controls obstructive physiology and symptoms, but does not establish that prior injury or all long-term excess risk has normalized. [1][12] | ||
| Quality of life / mood | OSA can impair health-related quality of life and mood. [10][12] | YES. Randomized evidence shows improvement in health-related quality of life and mood. [10][12] | SUBSTANTIAL BENEFIT, not universal normalization. These are established patient-centered PAP benefits. [10][12] | ||
| Daytime sleepiness / impaired alertness | One of the best-established direct consequences of OSA. [1][10] | YES. PAP clearly improves this, particularly in symptomatic patients. [1][10] | SUBSTANTIALLY, but not universally.Residual sleepiness can remain in some treated patients. [1][10] | ||
| Motor-vehicle crashes / accidents | OSA-related sleepiness substantially increases crash risk. [10][11] | Strong observational/real-world evidence of benefit. PAP treatment is associated with a major reduction in motor-vehicle crash risk. [11] | Risk greatly reduced, but normalization is not definitively established. This is nevertheless among the strongest real-world safety benefits of treatment. [11] | ||
| Premature death from all causes* | Moderate/severe OSA is associated with increased overall mortality. [1][2] | Observational (but not randomized) studies generally associate PAP with lower mortality and cardiovascular events. [2][15] | NOT DEMONSTRATED. Randomized trials have not shown a statistically significant reduction in overall mortality. The 2024 systematic review likewise found no demonstrated randomized-trial mortality benefit. [1][2][12][13] | ||
| Cardiovascular death* | OSA is associated with cardiovascular disease and cardiovascular mortality, particularly with greater severity and nocturnal hypoxemia. [1][5] | Observational (but not randomized) studies suggest PAP may reduce cardiovascular mortality. [2] | NOT DEMONSTRATED. Randomized trials have not independently established a significant reduction in cardiovascular death. [1][2][12][13] | ||
| Heart attack / coronary disease* | OSA is associated with coronary artery disease and myocardial infarction. [1][5] | PAP improves oxygenation, sympathetic stress and some cardiovascular risk factors. [5][9] | NOT DEMONSTRATED. Randomized trials have not demonstrated a significant reduction in myocardial infarction; the 2024 review found an effect estimate of 1.05. [1][12][13] | ||
| Stroke* | OSA is associated with stroke and cerebrovascular disease. [1][5] | PAP eliminates or greatly reduces nightly airway obstruction and hypoxemia while being used. [1] | NOT DEMONSTRATED. Randomized evidence has not demonstrated that PAP prevents stroke; the 2024 review found no significant reduction. [1][12][13] | ||
| High blood pressure / resistant hypertension | OSA can contribute causally to hypertension through intermittent hypoxia, sympathetic activation and related mechanisms. [3][5] | YES, PAP helps. Randomized evidence shows modest blood-pressure reductions, greatest when BP is uncontrolled. [3] | NOT ELIMINATED. PAP lowers BP but does not reliably eliminate hypertension or normalize BP in everyone. [3] | ||
| Atrial fibrillation and other arrhythmias | OSA is strongly associated with AF and creates conditions favoring arrhythmia and atrial remodeling. [4][5] | Observational studies often show markedly less recurrent AF in PAP users, particularly after ablation. [4] | NOT ESTABLISHED. In this 2025 post-ablation meta-analysis, 10 of 11 studies were observational; its single included randomized trial found no difference. [4] | ||
| Heart failure | OSA is associated with heart failure and adverse cardiac remodeling. [5] | PAP can improve nocturnal oxygenation, cardiac loading conditions and selected physiologic measures. [5] | NOT DEMONSTRATED. Evidence does not establish elimination of heart-failure risk or reversal of established cardiovascular disease. This row concerns OSA, not central sleep apnea. [1][5] | ||
| Type 2 diabetes / abnormal glucose metabolism | OSA is associated with insulin resistance and diabetes independently of obesity to at least some degree. [5] | PAP may improve insulin sensitivity in some patients. [5] | NOT DEMONSTRATED. Randomized evidence has not established prevention of diabetes or normalization of long-term glycemic risk. [1] | ||
| Cognitive impairment / dementia | OSA is associated with cognitive impairment and increased dementia risk in longitudinal literature, although causality remains uncertain. [16] | PAP can improve sleepiness and some cognitive functions; recent observational evidence suggests treatment may slow cognitive decline in some populations. [6] | NOT DEMONSTRATED. There is inadequate evidence that PAP eliminates dementia risk or fully reverses established neurocognitive effects; long-term trials are still needed. [6] | ||
| Chronic kidney disease / renal injury | OSA is associated with CKD and renal dysfunction; the relationship may be bidirectional. [7] | Some studies indicate improvements in renal measures with PAP. [7] | NOT DEMONSTRATED. Renal benefit remains uncertain; larger, longer randomized trials are needed. [7] | ||
| Cancer incidence / cancer death | OSA and particularly nocturnal hypoxemia have been associated with cancer incidence and mortality, although results are heterogeneous and causation remains uncertain. [8] | PAP has been proposed as potentially protective by reducing intermittent hypoxia. [8] | NOT ESTABLISHED. Randomized evidence is insufficient to determine whether PAP reduces cancer incidence or cancer mortality. [8] | ||
| Inflammation, sympathetic activation and vascular dysfunction | Repetitive hypoxia and arousals activate sympathetic, oxidative, inflammatory and vascular pathways. [5][9] | PAP suppresses the initiating nightly obstruction and improves several intermediate physiologic abnormalities. [9] | COMPLETE REVERSAL NOT DEMONSTRATED. Improvement in biomarkers or physiology does not establish reversal of pre-existing vascular or organ damage. [5][9] | ||
CITATIONS:
[1] Balk EM, Adam GP, Cao W, Bhuma MR, D’Ambrosio C, Trikalinos TA. Long-term effects on clinical event, mental health, and related outcomes of CPAP for obstructive sleep apnea: a systematic review. Journal of Clinical Sleep Medicine. 2024;20(6):895–909. doi:10.5664/jcsm.11030. PMID: 38300818. https://pmc.ncbi.nlm.nih.gov/articles/PMC11145052/ Review concluded that whether CPAP changes long-term health outcomes remains largely unanswered and found no statistically significant randomized-trial benefit for mortality, cardiovascular death, myocardial infarction, stroke, incident atrial fibrillation, or incident diabetes.
[2] Benjafield AV, Pepin J-L, Cistulli PA, et al. Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies. Lancet Respiratory Medicine. 2025;13(5):403–413. doi:10.1016/S2213-2600(25)00002-5. PMID: 40118084. https://pubmed.ncbi.nlm.nih.gov/40118084/ The pooled analysis favored PAP, whereas the randomized-trial subgroup did not establish a statistically significant all-cause mortality reduction.
[3] Pengo MF, et al. Effect of CPAP therapy on blood pressure in patients with obstructive sleep apnoea: a worldwide individual patient data meta-analysis. European Respiratory Journal. 2025;65(1):2400837. doi:10.1183/13993003.00837-2024. PMID: 39401854. https://pubmed.ncbi.nlm.nih.gov/39401854/ The analysis included 36 randomized studies and found the greatest blood-pressure benefit among patients whose blood pressure was uncontrolled at baseline.
[4] Itaya ED, et al. Efficacy of continuous positive airway pressure on atrial fibrillation recurrence after catheter ablation in patients with obstructive sleep apnea: a systematic review and meta-analysis. Journal of Interventional Cardiac Electrophysiology. 2025. doi:10.1007/s10840-025-02063-2. PMID: 40506608. https://pubmed.ncbi.nlm.nih.gov/40506608/ The meta-analysis included 10 observational studies and one RCT; the pooled observational evidence favored CPAP, while the single randomized trial showed no difference.
[5] Tasali E, Pamidi S, Covassin N, Somers VK. Obstructive Sleep Apnea and Cardiometabolic Disease: Obesity, Hypertension, and Diabetes. Circulation Research. 2025;137(5):764–787. doi:10.1161/CIRCRESAHA.125.325676. PMID: 40811500. https://pubmed.ncbi.nlm.nih.gov/40811500/ This contemporary review addresses the cardiovascular, autonomic, metabolic, inflammatory, and hypertensive consequences of OSA and the effects and limitations of CPAP treatment.
[6] Oliver C, Li H, Biswas B, et al. A systematic review on adherence to continuous positive airway pressure (CPAP) treatment for obstructive sleep apnoea (OSA) in individuals with mild cognitive impairment and Alzheimer’s disease dementia. Sleep Medicine Reviews. 2024;73:101869. doi:10.1016/j.smrv.2023.101869. PMID: 37924680. https://pubmed.ncbi.nlm.nih.gov/37924680/ Concluded that long-term, adequately powered efficacy trials are needed for whether CPAP slows cognitive decline in patients with MCI or Alzheimer disease.
[7] Peng HH, Hu CE, Wu YL, Liu WT, Tsai CY, Kuan YC. Effects of continuous positive airway pressure on renal function in adults with obstructive sleep apnea: a systematic review and meta-analysis. Sleep and Breathing.2025;29(1):102. doi:10.1007/s11325-025-03256-9. PMID: 39945962. https://doi.org/10.1007/s11325-025-03256-9 The review included 4 randomized and 7 non-randomized studies and concluded that current evidence suggests CPAP has little or no demonstrated effect on slowing renal-function decline, with larger and longer RCTs needed.
[8] Tan BKJ, Teo YH, Tan NK, Yap DWT, Sundar R, Lee CH, et al. Association of obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality: a systematic review and meta-analysis. Journal of Clinical Sleep Medicine. 2022;18(5):1427–1440. doi:10.5664/jcsm.9772. PMID: 34755597. https://pmc.ncbi.nlm.nih.gov/articles/PMC9059590/ The review found nocturnal hypoxemia associated with all-cancer risk and mortality, while emphasizing that further work is needed to determine whether OSA treatment alters cancer outcomes.
[9] Zhu Q, Luo Q, Wang Z, et al. Effects of continuous positive airway pressure therapy on inflammatory markers in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials. Sleep and Breathing.2025;29(2):182. doi:10.1007/s11325-025-03348-6. PMID: 40346316. https://pmc.ncbi.nlm.nih.gov/articles/PMC12064446/ Meta-analysis found reductions in inflammatory markers with CPAP treatment.
[10] Feltner C, Wallace IF, Aymes S, et al. Screening for Obstructive Sleep Apnea in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022;328(19):1951–1971. PMID: 36378203. https://pubmed.ncbi.nlm.nih.gov/36378203/ The review found that PAP significantly improves daytime sleepiness and sleep-related and general health-related quality of life, while evidence for most long-term clinical outcomes remains limited.
[11] Tregear S, Reston J, Schoelles K, Phillips B. Continuous positive airway pressure reduces risk of motor vehicle crash among drivers with obstructive sleep apnea: systematic review and meta-analysis. Sleep. 2010;33(10):1373–1380. doi:10.1093/sleep/33.10.1373. PMID: 21061860. https://pubmed.ncbi.nlm.nih.gov/21061860/ Meta-analysis found significant reduction in motor-vehicle crash risk with CPAP treatment.
[12] McEvoy RD, Antic NA, Heeley E, et al.; SAVE Investigators and Coordinators. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. New England Journal of Medicine. 2016;375(10):919-931. doi:10.1056/NEJMoa1606599. PMID: 27571048. https://pubmed.ncbi.nlm.nih.gov/27571048/ The SAVE trial enrolled predominantly minimally sleepy patients; mean CPAP use was 3.3 hours/night. It found no significant cardiovascular-event reduction but improved sleepiness, quality of life and mood.
[13] Sánchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, et al. Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis. JAMA. 2023;330(13):1255-1265. doi:10.1001/jama.2023.17465. PMID: 37787793. https://pubmed.ncbi.nlm.nih.gov/37787793/ Intention-to-treat analysis found no MACCE reduction; an on-treatment analysis associated good adherence (>=4 hours/day) with lower MACCE risk.
[14] Patil SP, Billings ME, Bourjeily G, Collop NA, Gottlieb DJ, Johnson KG, Kimoff RJ, Pack AI. Long-term health outcomes for patients with obstructive sleep apnea: placing the Agency for Healthcare Research and Quality report in context-a multisociety commentary. Journal of Clinical Sleep Medicine. 2024. doi:10.5664/jcsm.10832. PMID: 37904571. https://pubmed.ncbi.nlm.nih.gov/37904571/ Highlights limitations of long-term OSA outcome trials, including patient selection, adherence and ethical constraints on untreated symptomatic OSA.
[15] Mazzotti DR, Waitman LR, Miller J, et al. Positive Airway Pressure, Mortality, and Cardiovascular Risk in Older Adults With Sleep Apnea. JAMA Network Open. 2024;7(9):e2432468. doi:10.1001/jamanetworkopen.2024.32468. PMID: 39259540. https://pubmed.ncbi.nlm.nih.gov/39259540/ In 888,835 Medicare beneficiaries with OSA, PAP initiation/utilization was observationally associated with lower all-cause mortality and MACE incidence.
[16] Tian Q, Sun J, Li X, et al. Association between sleep apnoea and risk of cognitive impairment and Alzheimer’s disease: a meta-analysis of cohort-based studies. Sleep and Breathing. 2024;28(2):585-595. doi:10.1007/s11325-023-02934-w. PMID: 37857768. https://pubmed.ncbi.nlm.nih.gov/37857768/ The pooled cohort evidence found higher cognitive-impairment/dementia risk with OSA/SDB, while noting important diagnostic and causal limitations.
###
Veterans for Common Sense is a nonpartisan non-profit organization founded in 2002 by U.S. war veterans who honorably served our nation. Its principal purpose is to collect, analyze, and disseminate information relevant to U.S. foreign and military policy for the use of the public in better decision making. Veterans for Common Sense derived its name from the seminal “Common Sense” publication advocating for American independence authored by Founding Father Thomas Paine in 1776.
Last updated September 29, 2025
